Polyxeni Mavropoulou

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). PATIENTS AND METHODS Patients were randomized to receive daily erlotinib for 12 consecutive days prior to docetaxel (Arm A) or after docetaxel (Arm B). Progression-free(More)
  • 1